BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates

Company selects NewBridge Pharmaceuticals as regional distributor in Gulf Cooperation Council RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of…

Brukinsa® (zanubrutinib) capsules, for oral use

Name Brukinsa® (zanubrutinib) capsules Description Brukinsa® (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. Indication Indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at…

BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

BeiGene and NewBridge Pharmaceuticals are working together to rapidly advance BRUKINSA in the Middle East and North African (MENA) region CAMBRIDGE, Mass. & BEIJING & DUBAI, United Arab Emirates–(BUSINESS WIRE)– BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused…

Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals (“NewBridge”) for the distribution of RUCONEST® (conestat…

the CEO of NewBridge Pharmaceuticals Interview with TBY

The Business Year talks to Joe Henein, President and CEO of NewBridge Pharmaceuticals, on the global pharmaceuticals market, innovation, and the perception of the GCC market for overseas investors. https://www.thebusinessyear.com/dubai-2020/joe-henein-ceo-new-bridge-pharmaceuticals/vip-interview

the CEO of NewBridge Pharmaceuticals Interview with CNBC

Watch CNBC Arabia’s episode “Made in UAE” Documentary featuring Joe Henein, President and CEO of NewBridge Pharmaceuticals, and his colleagues talk about NewBridge’s Journey on its 10th year anniversary, highlighting…

CAPHOSOL® CAPHOSOL DISPERSIBLE®

Description Caphosol® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium…

Latuda

Name LATUDA® (Lurasidone) Description LATUDA® is a once-daily oral atypical antipsychotic. In addition to its well-demonstrated efficacy, LATUDA® with its favorable metabolic safety profile may be a solution for unmet…

COLLATAMP

Guardant360

Description Guardant360® assay is a liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw. Test results are available in approximately seven days upon receipt…